Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target
I'm PortAI, I can summarize articles.
Arthur He CFA from H.C. Wainwright maintains a Buy rating on Nektar Therapeutics, raising the price target to $135 due to promising Rezpeg trial results. The Phase 2b REZOLVE-AA study showed statistically significant results in a post-hoc analysis, indicating a stable treatment effect. The drug demonstrated a durable effect and favorable safety profile. Oppenheimer also maintains a Buy rating with a $115 price target. Arthur He is a 5-star analyst with a 32.2% average return and 52.76% success rate.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments